The TAXUS Express2 is a stainless steel stent that uses Paclitaxel and Translute polymer to control the drug release. Clinical trials consistently show low TLR and MACE rates compared to the bare metal control arm among a variety of patients and lesions. It is available in over-the-wire and monorail systems in a full product matrix, from 2.50 to 3.5 mm diameters and 8 to 32 mm lengths.
January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent ...
January 02, 2023 
December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...
December 23, 2022 
June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...
June 02, 2022 
February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...
February 16, 2022 
January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug ...
January 26, 2021 
Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...
October 19, 2020 
October 16, 2020 – Results from the XIENCE 90/28 clinical trials have shown that a shorter course of dual-antiplatelet ...
October 16, 2020 
October 11, 2019 — The ultra-thin Supraflex drug-eluting stent (DES) from SMT maintained numerically lower outcomes at ...
October 11, 2019 
September 30, 2019 – The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug ...
September 30, 2019 
September 30, 2019 — A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual ...
September 30, 2019